Romiplate Sales Forecast Summary

Key Factors Driving Romiplate Growth

Rising Prevalence and Diagnosis of Immune Thrombocytopenia (ITP)

One of the primary drivers for romiplostim growth is the increasing diagnosis of immune thrombocytopenia, a rare autoimmune disorder characterized by low platelet counts and increased bleeding risk.

• ITP incidence is estimated at 3–4 cases per 100,000 adults annually, with prevalence increasing due to improved diagnosis and longer patient survival.
• Chronic ITP often requires long-term therapy to maintain platelet counts and prevent bleeding events.

Romiplostim is widely used as a second-line treatment for adults and pediatric patients with chronic ITP who are refractory to corticosteroids, immunoglobulins, or splenectomy, which sustains demand for the therapy.

Proven Mechanism of Action and Clinical Effectiveness

Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that stimulates the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors, promoting platelet production in the bone marrow.

Key clinical benefits include:

• Significant increase in platelet counts in chronic ITP patients
• Reduced risk of bleeding events
• Ability to decrease or eliminate the need for rescue therapies

Clinical trials have demonstrated that approximately 80–90% of patients achieve platelet responses with romiplostim therapy, supporting its widespread clinical adoption.

Expanding Use Beyond Chronic ITP

Another important growth driver is the expansion of romiplostim use into additional thrombocytopenia-related conditions.

Emerging and approved uses include:

• Chemotherapy-induced thrombocytopenia (CIT)
• Thrombocytopenia associated with myelodysplastic syndromes (MDS)
• Investigational use in aplastic anemia and liver disease–associated thrombocytopenia

Expansion into additional hematology indications could increase the total addressable patient population.

Strong Commercial Sales and Continued Demand

Romiplostim has demonstrated steady commercial performance since its launch.

Key revenue data include:

• Q4 2025 sales: about USD 385 million, representing a 14% year-over-year increase, primarily driven by volume growth. 
• Full-year 2025 sales increased about 5%, also driven by higher demand. 
• Earlier reports showed strong prescription growth when excluding irregular U.S. government orders, with 12% underlying annual growth driven by 8% volume increases and higher net selling prices. 

These figures indicate continued demand from physicians treating chronic thrombocytopenia.

Global Expansion and Increasing Physician Adoption

Romiplostim is approved across major markets including:

• United States
• European Union
• Japan and other Asian markets

Increasing awareness of TPO-receptor agonists among hematologists and improved treatment guidelines for chronic ITP are contributing to higher global prescription volumes.

In addition, growing adoption in pediatric ITP populations and earlier lines of therapy further support market expansion.

Romiplate Recent Developments

• Kyowa Kirin received approval for a partial change in the manufacturing and marketing approval of Romiplate to treat aplastic anemia (AA) in patients without prior immunosuppressive agent treatment, addressing unmet medical needs for patients with inadequate responses to existing therapies. The global market for Romiplostim is expected to experience continued growth through 2034, driven by rising health awareness and increased adoption in managing chronic autoimmune disorders.

“Romiplate Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Romiplate for approved indication like Aplastic anaemia, Idiopathic thrombocytopenic purpura, Acute radiation syndrome; as well as potential indication like Thrombocytopenia and Myelodysplastic syndromes in the 7MM. A detailed picture of Romiplate’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Romiplate for approved and potential indications. The Romiplate market report provides insights about Romiplate’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Romiplate performance, future market assessments inclusive of the Romiplate market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Romiplate sales forecasts, along with factors driving its market.

Romiplate Drug Summary

Romiplate is an FDA-approved (as Nplate) and internationally marketed recombinant Fc-peptide fusion protein (peptibody) developed by Amgen and Kyowa Kirin that acts as a thrombopoietin receptor agonist, binding and activating the c-Mpl (TPO) receptor on megakaryocytes and platelets to stimulate platelet production independent of endogenous thrombopoietin. Indicated for thrombocytopenia in adult and pediatric patients with chronic immune thrombocytopenia (ITP) refractory to corticosteroids, immunoglobulins, or splenectomy, as well as adults with moderate to severe aplastic anemia unresponsive to immunosuppressive therapy, it is administered weekly as a subcutaneous injection (starting at 1-10 mcg/kg based on platelet counts, titrated to maintain 50-200 x 10^9/L). The molecule consists of two identical subunits—each with a human IgG1 Fc domain covalently linked to peptide chains containing four thrombopoietin receptor-binding domains—offering a novel mechanism to increase platelet counts, reduce bleeding risk, and potentially bridge to hematopoietic stem cell transplantation, with monitoring required for thrombocytopenia rebound, bone marrow fibrosis, and neutralizing antibodies. The report provides Romiplate’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the Romiplate Market Report 

The report provides insights into:

• A comprehensive product overview including the Romiplate MoA, description, dosage and administration, research and development activities in approved indications like Aplastic anaemia, Idiopathic thrombocytopenic purpura, Acute radiation syndrome; as well as potential indication like Thrombocytopenia and Myelodysplastic syndromes.
• Elaborated details on Romiplate regulatory milestones and other development activities have been provided in Romiplate market report.
• The report also highlights Romiplate‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan. 
• The Romiplate market report also covers the patents information, generic entry and impact on cost cut.
• The Romiplate market report contains current and forecasted Romiplate sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Romiplate market report also features the SWOT analysis with analyst views for Romiplate in approved and potential indications.

Romiplate Market Report Methodology

The Romiplate market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Romiplate Analytical Perspective by DelveInsight

• In-depth Romiplate Market Assessment

This Romiplate sales market forecast report provides a detailed market assessment of Romiplate for approved indication like Aplastic anaemia, Idiopathic thrombocytopenic purpura, Acute radiation syndrome; as well as potential indication like Thrombocytopenia and Myelodysplastic syndromes in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Romiplate sales data uptil 2034.

• Romiplate Clinical Assessment

The Romiplate market report provides the clinical trials information of Romiplate for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Romiplate Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Romiplate Market Potential & Revenue Forecast

• Projected market size for the Romiplate and its key indications
• Estimated Romiplate sales potential (Romiplate peak sales forecasts)
• Romiplate Pricing strategies and reimbursement landscape

Romiplate Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Romiplate Market positioning compared to existing treatments
• Romiplate Strengths & weaknesses relative to competitors

Romiplate Regulatory & Commercial Milestones

• Romiplate Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Romiplate Clinical Differentiation

• Romiplate Efficacy & safety advantages over existing drugs
• Romiplate Unique selling points  

Romiplate Market Report Highlights 

• In the coming years, the Romiplate market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Romiplate companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Romiplate’s dominance.
• Other emerging products for Aplastic anaemia, Idiopathic thrombocytopenic purpura, Acute radiation syndrome; as well as potential indication like Thrombocytopenia and Myelodysplastic syndromes are expected to give tough market competition to Romiplate and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Romiplate in approved and potential indications.
• Analyse Romiplate cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Romiplate sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Romiplate in approved and potential indications. 

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Romiplate? How strong is Romiplate’s clinical and commercial performance?
• What is Romiplate’s clinical trial status in each individual indications such as Aplastic anaemia, Idiopathic thrombocytopenic purpura, Acute radiation syndrome; as well as potential indication like Thrombocytopenia and Myelodysplastic syndromes and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Romiplate Manufacturers?
• What are the key designations that have been granted to Romiplate for approved and potential indications? How are they going to impact Romiplate’s penetration in various geographies?
• What is the current and forecasted Romiplate market scenario for approved and potential indications? What are the key assumptions behind the forecast? 
• What are the current and forecasted sales of Romiplate in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Romiplate for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Romiplate? What is the duration of therapy and what are the geographical variations in cost per patient?